We are live on ! Find out more
VMI

VHCP Management II Portfolio holdings

AUM $379M
1-Year Est. Return 421.62%
This Fund
S&P 500
This Quarter Est. Return
+37.65%
1 Year Est. Return
+421.62%
3 Year Est. Return
+2,333.62%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$362M
AUM Growth
+$112M
Cap. Flow
+$31.3M
Cap. Flow %
8.65%
Top 10 Hldgs %
91.12%
Holding
24
New
5
Increased
3
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$12.3M
2
OBSV
ObsEva SA Ordinary Shares
OBSV
+$9.52M
3
ASND icon
Ascendis Pharma A/S
ASND
+$8.97M
4
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$8.45M
5
BLPH
Bellerophon Therapeutics, Inc.
BLPH
+$5.14M

Top Sells

Rank Stock Value
1
PDSB icon
PDS Biotechnology
PDSB
+$6.76M
2
XLRN
Acceleron Pharma
XLRN
+$4.77M
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$4.76M
4
CTMX icon
CytomX Therapeutics
CTMX
+$4.48M
5
OCRX
Ocera Therapeutics, Inc.
OCRX
+$794K

Sector Composition

Rank Sector Weight
1 Healthcare 92.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVXS
1
DELISTED
AveXis, Inc. Common Stock
AVXS
$100M 27.68%
1,035,657
– –
BHVN
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$60.8M 16.81%
1,664,300
– –
ASND icon
3
Ascendis Pharma A/S
ASND
$17.1B
$47.1M 13.01%
1,299,052
+312,560
+32% +$8.97M
ZGNX
4
DELISTED
Zogenix, Inc.
ZGNX
$31.8M 8.78%
+907,057
New +$12.3M
BCRX icon
5
BioCryst Pharmaceuticals
BCRX
$2.36B
$16.6M 4.58%
3,165,457
+690,290
+28% +$3.53M
ARGX icon
6
argenx
ARGX
$53.8B
$14.5M 4%
647,015
– –
PDSB icon
7
PDS Biotechnology
PDSB
$41.1M
$13.7M 3.79%
63,963
-32,716
-34% -$6.76M
OBSV
8
DELISTED
ObsEva SA Ordinary Shares
OBSV
$11.4M 3.15%
1,401,343
+1,251,343
+834% +$9.52M
MYOK
9
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$11.4M 3.14%
+265,000
New +$8.45M
RARX
10
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$11.2M 3.11%
769,771
– –
ANAB icon
11
AnaptysBio
ANAB
$1.72B
$5.86M 1.62%
+167,550
New +$4.52M
BLPH
12
DELISTED
Bellerophon Therapeutics, Inc.
BLPH
$4.72M 1.3%
+276,625
New +$5.14M
AKTX
13
Akari Therapeutics
AKTX
$19.3M
$2.62M 0.72%
533
– –
LPCN icon
14
Lipocine
LPCN
$18.4M
$1.54M 0.42%
22,760
– –
KALV
15
DELISTED
KalVista Pharmaceuticals
KALV
$1.49M 0.41%
221,651
– –
MDGL icon
16
Madrigal Pharmaceuticals
MDGL
$12.8B
$1.35M 0.37%
+30,000
New +$561K
ORKA
17
Oruka Therapeutics
ORKA
$5.59B
$1.24M 0.34%
4,995
– –
ADVM
18
DELISTED
Adverum Biotechnologies
ADVM
$1.02M 0.28%
28,000
– –
OCRX
19
DELISTED
Ocera Therapeutics, Inc.
OCRX
$544K 0.15%
477,269
-740,603
-61% -$794K
SIOX
20
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$524K 0.14%
9,520
-28,195
-75% -$4.76M
CTMX icon
21
CytomX Therapeutics
CTMX
$788M
– –
-288,915
Closed -$4.48M
SRRA
22
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-3,270
Closed -$153K
XLRN
23
DELISTED
Acceleron Pharma
XLRN
– –
-156,880
Closed -$4.77M

Similar funds

ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
PI
PHH Investments Addison, Texas $378M AUM 19.74% 1-Year Est. Return
SC
Southside Capital Miami Beach, Florida $382M AUM 30.29% 1-Year Est. Return
FFSOTS
Fiduciary Financial Services of The Southwest Dallas, Texas $382M AUM 25.98% 1-Year Est. Return
PC
Passport Capital San Francisco, California $394M AUM 50.67% 1-Year Est. Return
WC
Whitnell & Co Oak Brook, Illinois $326M AUM 25.97% 1-Year Est. Return
VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
LB
Landmark Bank Columbia, Missouri $444M AUM 30.12% 1-Year Est. Return

VHCP Management II's Q3 2017 Portfolio in Review

As of Q3 2017, VHCP Management II held 24 positions worth $362M, up 45% from $250M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

VHCP Management II deployed $31.3M of net new capital in Q3 2017, opening 5 new positions and adding to 3 existing holdings. Its largest new stake was Zogenix, Inc.: 907,057 shares worth $31.8M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 92% a quarter earlier.

On the sell side, the largest reduction was PDS Biotechnology, an estimated $6.76M trimmed.

  • VHCP Management II's largest Q3 2017 buy was Zogenix, Inc.: 907,057 shares worth $31.8M.
  • VHCP Management II added most to ObsEva SA Ordinary Shares in Q3 2017, an estimated $9.52M increase.
  • VHCP Management II's biggest Q3 2017 reduction was PDS Biotechnology, cutting an estimated $6.76M.
  • VHCP Management II fully exited Acceleron Pharma in Q3 2017, selling an estimated $4.77M.
  • VHCP Management II's ten largest holdings make up 91% of its $362M portfolio in Q3 2017.
  • VHCP Management II opened 5 new positions and closed 3 in Q3 2017.
  • VHCP Management II's portfolio value rose 45% quarter-over-quarter to $362M.

Based on VHCP Management II's 13F filing for Q3 2017, filed 13 Nov 2017.